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ABSTRACT 1 
The abundant, nuclear-retained, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) 2 
has been associated with a poorly differentiated and aggressive phenotype of mammary carcinomas. 3 
This long non-coding RNA (lncRNA) localizes to nuclear speckles, where it interacts with a subset 4 
of splicing factors and modulates their activity. In this study, we demonstrate that oncogenic 5 
splicing factor SRSF1 bridges MALAT1 to mutant p53 and ID4 proteins in breast cancer cells. 6 
Mutant p53 and ID4 delocalize MALAT1 from nuclear speckles and favor its association with 7 
chromatin. This enables aberrant recruitment of MALAT1 on VEGFA pre-mRNA and modulation 8 
of VEGFA isoforms expression. Interestingly, VEGFA-dependent expression signatures associate 9 
with ID4 expression specifically in basal-like breast cancers carrying TP53 mutations. Our results 10 
highlight the key role for MALAT1 in control of VEGFA isoforms expression in breast cancer cells 11 
expressing gain-of-function mutant p53 and ID4 proteins. 12 
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INTRODUCTION 1 
The eukaryotic genome harbors a large number of noncoding RNAs, which include small and long 2 
noncoding RNAs (lncRNAs). The nuclear-retained Metastasis-Associated Lung Adenocarcinoma 3 
Transcript 1 (MALAT1), also known as Nuclear-Enriched Abundant Transcript 2 (NEAT2), is one 4 
of the most abundant and highly-conserved lncRNAs and is overexpressed in several cancers; its 5 
elevated expression has been associated with hyper-proliferation, metastasis and poor prognosis [1-6 
5]. 3'-end processing of MALAT1 has been shown to yield a tRNA-like cytoplasmic RNA [6, 7]. 7 
MALAT1 localizes to nuclear speckles, a sub-nuclear domain suggested to coordinate RNA 8 
polymerase II transcription, pre-mRNA splicing and mRNA export [8-11]. MALAT1 interacts with 9 
several pre-mRNA splicing factors [12-14] including serine-arginine dipeptide-rich SR-family 10 
splicing factors such as SRSF1 (also known as ASF/SF2), SC35 (SRSF2), and SRSF3. This 11 
lncRNA has been shown to induce the expression of cell cycle genes and to control alternative 12 
splicing of pre-mRNAs by modulating the intranuclear distribution of SR splicing factors [15, 16]. 13 
Interestingly, knockdown of MALAT1 has no impact on the formation, size and number of nuclear 14 
speckles, whereas it does result in a decreased nuclear speckle association of several pre-mRNA 15 
splicing factors, including SRSF1 [10, 17, 18].  16 
SRSF1, a prototype member of the SR protein family mostly recruited to exonic splicing enhancers 17 
(ESEs), is a multifunctional RNA-binding protein with roles in pre-mRNA constitutive and 18 
alternative splicing, mRNA export and mRNA translation; it was identified as an oncogene due to 19 
its transforming capacity in vitro and in vivo [19-23]. Activity of SRSF1 is crucial for alternative 20 
splicing control of the terminal exon of the VEGFA gene, a major determinant in tumor neo-21 
angiogenesis [24]. Two families of VEGFA isoforms are indeed generated by alternate splice-site 22 
selection in the gene’s terminal exon, exon 8. Proximal splice-site selection (PSS) in exon 8 results 23 
in proangiogenic VEGFAxxx isoforms (xxx is the number of amino acids), whereas distal splice-site 24 
selection (DSS) results in antiangiogenic VEGFAxxxb isoforms [25-29]. SRSF1 has been shown to 25 
favour PSS selection in exon 8 during VEGFA pre-mRNA splicing [26]. The antiangiogenic 26 
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VEGFAxxxb isoform is downregulated in several epithelial cancer types and in other pathologies 1 
associated with abnormal neovascularization [30-32]. VEGFA165b inhibits VEGFR2 signaling by 2 
inducing differential phosphorylation, and it can be used to block angiogenesis in in vivo models of 3 
tumorigenesis. Recombinant human VEGFA165b (rhVEGFA165b) treatment in vivo also has a 4 
growth-inhibitory effect in nude mice xenograft models of various tumours [33-36]. VEGFA165 and 5 
VEGFA121 are among the most abundant proangiogenic VEGFA isoforms in cancer cells and have 6 
been very recently shown to exert opposite effects on the growth and invasion of tumor cells in vivo 7 
[37]. 8 
We previously characterized a molecular network whereby gain-of-function mutant p53 (mtp53) 9 
proteins are responsible for induction of the ID4 protein in breast cancer [38]. Mtp53 proteins are 10 
peculiarly characterized by a prolonged half-life compared with that of the wt-p53 protein and many 11 
mtp53 proteins show the inability to recognize wt-p53 DNA-binding sites. Many of these mtp53 12 
proteins presenting high levels of expression in cancer cells have been also demonstrated to have 13 
various oncogenic properties [39-41]; many mtp53 proteins have indeed been shown to present 14 
gain-of-function (GOF) activity, positively contributing to tumorigenesis in vivo and conferring 15 
increased aggressiveness phenotype to cell lines in vitro [42]. 16 
ID4 protein expression is enriched in breast cancer tissues exhibiting p53 over-expression 17 
(indicating the presence of a TP53 gene mutation). The net biological output of the transcriptional 18 
activation of the ID4 gene by mutant p53 is the increase of the angiogenic potential of mutant p53-19 
carrying tumor cells. Despite the absence of an RNA-binding domain in its protein sequence, ID4 20 
protein has been shown to interact, probably indirectly, with the mRNAs of pro-angiogenic factors 21 
and to increase their stability and rate of translation [38, 43]. Accordingly, high ID4 protein 22 
expression is associated with high microvessel density in breast cancer [38]. Several studies have 23 
shown that high ID4 mRNA and protein expressions are associated with the highly aggressive 24 
basal-like subtype of breast cancer (BLBC), characterized by a substantially high incidence of TP53 25 
gene mutations (nearly 80%), expression of basal cytokeratins, and absence of estrogen, 26 
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progesterone and ERBB2 receptors [44-47]. High ID4 expression in BLBC has been related to poor 1 
disease-free and overall survival [47, 48]. A recent study showed that ID4 is a key regulator of 2 
mammary stem cell self-renewal and marks a subset of BLBC with a putative mammary basal cell 3 
origin [48].  4 
The present study aimed to identify mediators of ID4-associated pro-angiogenic activity in breast 5 
cancer. We report the identification of a quaternary ribonucleoprotein (RNP) complex comprising 6 
the MALAT1 lncRNA and the SRSF1 oncogenic splicing factor, as well as mutant p53 and ID4 7 
proteins. This RNP complex is recruited on VEGFA pre-mRNA, where it inhibits the synthesis of 8 
anti-angiogenic VEGFAxxxb isoforms. Accordingly, the depletion of MALAT1 or of any of the 9 
protein components of this RNP complex leads to a reduction in the angiogenic potential of breast 10 
cancer cells. Moreover, high ID4 expression is associated with an enriched VEGFA-activity 11 
expression signature specifically in mutant p53-carrying basal-like breast cancer.  12 
 13 
 14 
RESULTS 15 
Splicing factor SRSF1 stabilizes the binding of ID4 and mutant p53 proteins to lncRNA 16 
MALAT1 in breast cancer cells. We previously showed that mutant p53 proteins induce ID4 17 
expression in breast cancer cells. ID4 protein is able to bind to the mRNAs encoding pro-angiogenic 18 
cytokines and favors their translation, resulting in enhanced neoangiogenesis [38, 43].  19 
To identify additional mediators of angiogenesis controlled by ID4, we performed a RIP-chip 20 
analysis (Ribonucleoprotein ImmunoPrecipitation followed by microarray analysis) in MDA-MB-21 
468 breast cancer cells, which led to the identification of a panel of RNAs bound by ID4 (Appendix  22 
Tables S1 and S2). Interestingly, among ID4-targeted RNAs, we identified MALAT1, a long non-23 
coding RNA (lncRNA) that has been reported to modulate active Serine/Arginine-rich (SR) proteins 24 
in the nucleus. SR proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) are the major 25 
classes of splicing factors that select splice sites for recognition by the spliceosome through binding 26 
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to intronic or exonic splice elements. The expression of specific isoforms of VEGFA, a major 1 
player in tumour angiogenesis, depend on the SR family protein SRSF1, whose activity is in turn 2 
controlled by MALAT1; for this reason we explored the possibility that ID4 controls VEGFA 3 
expression by modulating MALAT1 and SRSF1 activities. 4 
Using native lysates from different breast cancer cell lines, we confirmed by RIP assays that ID4 5 
binds to MALAT1 (Figure 1A-B and Appendix Figure S1A). Interaction between ID4 protein and 6 
MALAT1 lncRNA was also confirmed by RIP assay in MDA-MB-468 cells overexpressing HA-7 
tagged ID4 protein (Appendix Figure S1B). Interestingly, we observed that also the mutant p53 8 
(mtp53) proteins p53R175H (endogenously expressed in SKBR3 cells) and p53R273H 9 
(endogenously expressed in MDA-MB-468 and OVCAR-3 cells) are able to bind to this lncRNA 10 
(Figure 1C and Figure EV1A). Combined immunofluorescence for p53 and RNA FISH for 11 
MALAT1 showed colocalization of mtp53 protein and MALAT1 in MDA-MB-468 and SKBR3 12 
cells (Figure 1D-E and Figure EV1B).  13 
On the contrary, immunoprecipitation of endogenous wild-type p53 in MCF7 breast cancer and in 14 
breast-derived MCF10A cells, in which wt-p53 was stabilized or not by a DNA-damaging agent, 15 
evidenced no binding to MALAT1 (Figure EV1C-E). Of note, also ID4 protein did not bind to 16 
MALAT1 in these wt-p53 cell contexts (Figure EV1E). Interestingly, staining of MALAT1 RNA 17 
by FISH assay evidenced different patterns of intranuclear localization in MCF7 and MDA-MB-468 18 
cells, with MCF7 cells showing MALAT1 mainly localized in speckles and MDA-MB-468 19 
showing also a diffused localization of MALAT1, beyond the speckles (Figure EV1F). 20 
We decided to investigate whether ID4 and mtp53 bind to MALAT1 directly or other RNA-binding 21 
proteins mediate their binding to MALAT1. To this end we performed RIP experiments using 22 
lysates from cells crosslinked with formaldehyde, which leads to protein:protein and protein:RNA 23 
covalent links, or with U.V. light, which links covalently interacting protein:RNA avoiding 24 
protein:protein crosslinks. As shown in Figures 1A and 1C, ID4 and p53 proteins bind to MALAT1 25 
only in cells crosslinked with formaldehyde, indicating these as indirect interactions.  26 
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One of the best-characterized MALAT1-dependent factors is the oncogenic splicing factor SRSF1, 1 
which has been shown to be upregulated in breast cancer and to promote transformation of 2 
mammary cells [19, 20]. To explore whether SRSF1 is responsible for the binding of ID4 and 3 
mutant p53 proteins to MALAT1, we first performed RIP experiments in MDA-MB-468 cells to 4 
determine whether SRSF1 protein actually interacts with MALAT1 in our experimental setting. 5 
SRSF1 has been demonstrated to interact directly with MALAT1 [13]. Consistent with these 6 
published data [10, 13], we observed a strong enrichment specifically for MALAT1 lncRNA, and 7 
not for NEAT1 lncRNA (not interacting with MALAT1 in previous reports [10]), among the RNAs 8 
immunoprecipitated with anti-SRSF1 antibody compared to IgG negative control, in native lysates 9 
as well as in lysates from cells crosslinked with formaldehyde and U.V. light (Figure 1F).  10 
Of note, depletion of SRSF1 expression (Figure 1G and Figure EV1G) in MDA-MB-468 cells 11 
significantly decreased the binding of ID4 and mutant p53 proteins to MALAT1, as assessed by 12 
RIP assay (Figure 1H). 13 
 14 
Mutant p53 and ID4 interact with SRSF1 in a MALAT1-dependent manner. We next explored 15 
whether ID4 and mutant p53 proteins interact with splicing factor SRSF1. Using a Proximity 16 
Ligation Assay (PLA), we first assessed that both ID4 and mutant p53 interact with SRSF1 in 17 
MDA-MB-468 and SKBR3 cells (Figure 2A-B, si-SCR; Figure EV2A). An interaction between 18 
ID4 and mutant p53 was also detected (Figure 2C, si-SCR; Figure EV2A). Importantly, depletion of 19 
MALAT1 (Figure 2D-E) by RNA interference significantly reduced the number of ID4-SRSF1 and 20 
mutant p53-SRSF1 interactions (Figure 2A-B,; Figure EV2A-C), indicating that these are RNA-21 
dependent interactions.  22 
In contrast, the mutant p53-ID4 interaction was not affected by MALAT1 interference (Figure 2C; 23 
Figure EV2A-C) or by SRSF1 interference (Figure EV2D-E).  24 
As a control for the specificity of the mutant p53-SRSF1 interaction, we analyzed this complex by 25 
PLA assay in parental MDA-MB-468, as well as in the same cell strain with stable depletion of 26 
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endogenous mutant p53 expression (sh-p53). Analysis of p53 levels in these stable cell lines is 1 
shown in Appendix Figure S1C. As shown in Figure 2F-G, the mutant p53-SRSF1 interaction was 2 
strongly reduced upon mutant p53 depletion (sh-p53).  3 
The interaction between mutant p53 and SRSF1 proteins was also detected in Co-4 
ImmunoPrecipitation (Co-IP) experiments using p53-null H1299 cells transfected with a mutant 5 
p53R273H expression vector or an empty vector as negative control (Figure 2H). 6 
Immunoprecipitation of ID4 protein followed by western blot of p53 and SRSF1 in the same cells 7 
showed the existence of ID4-p53R273H and ID4-SRSF1 complexes (Figure 2I). Co-IP experiments 8 
in SKBR3 cells evidenced the mutant p53R175H-SRSF1 complex, which was impaired when lysate 9 
was treated with RNaseA or when cells were depleted of SRSF1 expression (Figure 2J).  10 
 11 
Mutant p53 and ID4 stabilize binding of SRSF1 to MALAT1. We next raised the question of 12 
whether mutant p53 and ID4 expression influence the binding of SRSF1 to MALAT1. To this end, 13 
MDA-MB-468 cells were transfected with si-RNAs directed to p53 or ID4 mRNAs (Figure 3A-B), 14 
and cell extracts were used to immunoprecipitate SRSF1. Importantly, mutant p53 or ID4 depletion 15 
reduced SRSF1 binding to MALAT1 (Figure 3C). It has been reported that MALAT1 RNA 16 
contains several SRSF1 binding sites that are distributed along the whole sequence of the transcript 17 
[10, 13]. RIP assays for SRSF1, performed in cells subjected to crosslinking and sonication, 18 
followed by analysis of enrichments on 14 regions spanning the whole MALAT1 RNA, evidenced a 19 
major site of enrichment in the 5’ half of MALAT1 (Figure 3D). Additional regions significantly 20 
enriched were also identified along MALAT1 RNA. Depletion of ID4 caused reduction of SRSF1 21 
binding to MALAT1 in all the enriched regions (Figure 3D), while its interaction with other well 22 
established target pre-mRNAs wasn’t significantly affected (Figure EV3A). Interestingly, ID4 23 
depletion also impaired binding of SRSF1 protein to mutant p53, as assessed by PLA assay (Figure 24 
3E and Figure EV3B). 25 
As reciprocal approach we performed a ChIRP assay (Chromatin Isolation by RNA Purification) 26 
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[49]. Specifically, MALAT1-associated proteins and RNAs were recovered by using a series of 1 
biotinylated oligonucleotides spanning the whole MALAT1 sequence, in control MDA-MB-468 2 
cells (si-SCR), as well as in ID4-depleted (si-ID4) and mutant p53-depleted (si-p53) cells (Figure 3 
3F). Efficiency in MALAT1 RNA recovery was checked by RT-qPCR (Figure 3G). Interaction of 4 
MALAT1 with ID4 and p53 was analyzed by a dot-blot assay, as western blotting was not 5 
applicable due to irreversible crosslinking by glutaraldehyde used to fix the cells in this protocol 6 
[49]. As shown in Figure 3H, lower amounts of SRSF1 were found to be associated with MALAT1 7 
RNA in cells depleted of ID4 or mutant p53 compared with control cells.  8 
 9 
Mutant p53 and ID4 control intranuclear localization of MALAT1. It has been previously 10 
reported that MALAT1 controls alternative splicing by interacting with SR proteins and influencing 11 
the distribution of these and other splicing factors in nuclear speckle domains [10]. Nuclear 12 
speckles do not represent major sites of transcription or splicing, but rather are considered sites 13 
from where splicing factors are recruited to active sites of transcription.  14 
To analyze whether mutant p53 or ID4 expression influences the subcellular localization of 15 
MALAT1, we performed RNA FISH experiments in MDA-MB-468 and SKBR3 cells after mutant 16 
p53 or ID4 depletion. In both cell lines we observed a mixed cell population, composed of cells 17 
showing speckled localization of MALAT1 and cells showing diffused plus speckled staining 18 
(representative images in Figure EV3C).  19 
As shown in Figure 4A, ID4 or mutant p53 depletion affected MALAT1 intranuclear localization in 20 
both cell lines, leading to a significant increase in the number of cells showing MALAT1 localized 21 
in speckles (Figure 4A).  22 
By confocal microscopy analysis, we also noticed an increase in the size of MALAT1-positive 23 
speckles in cells depleted of ID4 or mutant p53 (representative images in Figure 4B). 24 
As a higher MALAT1 diffused localization occurs in cells expressing ID4 and mutant p53, we 25 
investigated whether ID4 and mutant p53 modulated the localization of MALAT1 on chromatin. To 26 
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test this, we analyzed the association between MALAT1 and histone H3 protein. Histone H3 protein 1 
is indeed localized exclusively in the chromatin-associated nuclear fraction in the breast cancer cell 2 
lines used in our study (Figure EV3D-E). Accordingly, MALAT1-associated proteins were 3 
retrieved using biotinylated oligonucleotides complementary to MALAT1 lncRNA, and the 4 
presence of histone H3 was evaluated by a dot-blot assay. As shown in Figure 4C, similar amounts 5 
of MALAT1 lncRNA were isolated in control and in ID4-depleted or mutant p53-depleted cells. Of 6 
note, we observed that histone H3 protein was enriched in samples in which biotinylated 7 
oligonucleotides complementary to MALAT1 (Bio-MALAT1) were used compared to samples 8 
using negative control oligonucleotides (Bio-CTR) (Figure 4D-E). Importantly, the amount of 9 
MALAT1-associated histone H3 clearly decreased after ID4 or mutant p53 interference, suggesting 10 
that ID4 and mutant p53 favor the localization of MALAT1 to chromatin regions containing H3 11 
(Figure 4D-E). Accordingly, analysis of MALAT1-associated RNAs by RT-qPCR showed that U2 12 
snRNA, which was reported to be mostly localized in nuclear speckles, is enriched in Bio-13 
MALAT1 versus Bio-CTR samples and that, importantly, its enrichment increases after depletion of 14 
ID4 or mutant p53 (Figure 4F).  15 
As reciprocal approach, in RIP assays we immunoprecipitated histone H3 protein and evaluated 16 
recovery of MALAT1 RNA in control and mtp53-/ID4-depleted cells (Figure 4G-H). As shown in 17 
Figure 4I-J, we observed a decrease in MALAT1 RNA recovery in cells depleted of mtp53/ID4 18 
compared to control cells (si-SCR). The same experiment was performed using antibodies directed 19 
to modified histone H3 forms, such as H3K36me3 (specifically enriched in exons and able to 20 
interact with SRSF1) [50-52] and H3K27Ac (generally associated with active transcription). 21 
H3K36me3 showed a behavior similar to H3, while H3K27Ac was decreased following mtp53/ID4 22 
depletion only in MDA-MB-468 cells (Figure 4I-J). 23 
Altogether, these findings indicate that mutant p53 and ID4 proteins may enhance MALAT1 24 
availability at sites of active transcription/splicing. 25 
 26 
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Mutant p53, ID4, SRSF1 and MALAT1 modulate VEGFA isoforms expression in breast 1 
cancer cells. VEGFA is a major player in tumour angiogenesis and exists in multiple splicing 2 
isoforms, including the most abundant VEGFA165 and VEGFA121 (outlined in Figure 5A). 3 
Moreover, VEGFA may be expressed in cells as pro- and anti-angiogenic splicing variants. Anti-4 
angiogenic isoforms, named VEGFAxxxb, arise from an alternative 3' splice site in exon 8 and differ 5 
from VEGFAxxx by six amino acids at the C-terminus (Figure 5A). These alternative six amino 6 
acids radically change the functional properties of VEGFA. SRSF1 protein, interestingly, was 7 
reported to favor proximal splice site (PSS) selection during splicing of the VEGFA transcript, 8 
increasing the production of pro-angiogenic isoforms [26]. 9 
We explored whether the identified ribonucleoprotein (RNP) complex affects the abundance of 10 
VEGFA isoforms. As VEGFA165 and VEGFA121 are the most abundantly expressed isoforms in 11 
cancer cells we analyzed by RT-qPCR the expression of their pro- (VEGFA165 and VEGFA121) and 12 
anti- (VEGFA165b and VEGFA121b) angiogenic forms in control MDA-MB-468 cells and in cells 13 
depleted of ID4, mutant p53, MALAT1 or SRSF1. We first evaluated the mRNA ratio between 14 
anti- and pro-angiogenic VEGFA isoforms. As shown in Figure 5B, the depletion of each 15 
component of the RNP complex led to increased 165b/165 and 121b/121 ratios. Depletion of 16 
hnRNP A1 (a known negative regulator of SRSF1) shows opposite effect on 165b/165 ratio, 17 
compared to si-SRSF1 (Figure 5B and Figure EV4A). 18 
We next analyzed VEGFA protein expression by using antibodies specifically recognizing 19 
VEGFA165b or total VEGFA. According to RT-qPCR results, we observed that selective depletion 20 
of mutant p53, ID4, SRSF1 or MALAT1 expression in MDA-MB-468 and SKBR3 cells led to 21 
increased VEGFA165b protein level (Figure 5C-D). Increase of VEGFA165b protein level was also 22 
confirmed by using additional siRNAs for mutant p53, ID4, SRSF1 and MALAT1 depletion in 23 
MDA-MB-468, SKBR3 and MDA-MB-231 cells (Figure EV4C-G).  24 
We also evaluated the ratio between isoforms VEGFA121 and VEGFA165. As shown in Figure 5E, a 25 
decreased 121/165 ratio was observed in cells depleted of mutant p53, MALAT1 or SRSF1, and a 26 
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decreased 121b/165b ratio was present in all the analyzed siRNA conditions, suggesting that this 1 
complex might favor the shorter VEGF121 and VEGF121b expression. An effect opposite to that of 2 
si-SRSF1 on 121b/165b ratio was observed upon depletion of hnRNP A1 (Figure 5E). As a control, 3 
we analyzed the effect of the depletion of ID4, mutant p53, MALAT1 or SRSF1 on the production 4 
of two isoforms of the housekeeping gene Aldolase-A (ALDOA), differing for the 5 
inclusion/exclusion of an exon (Figure EV4B), and we observed no significant modulation upon 6 
interference of all components, except SRSF1, whose depletion led to the reduction of the analyzed 7 
isoforms ratio (Figure EV4B). 8 
We next evaluated the expression levels of the various VEGFA isoforms in the RNA-seq dataset 9 
from the breast cancer TCGA study. This dataset allowed only the analysis of VEGF121 and 10 
VEGF165 expression, as VEGFAxxxb isoform detection is at low levels in this dataset. By comparing 11 
tumors with missense mutations in the TP53 gene with wt-p53 carrying tumors we observed that, 12 
despite VEGF165 being the predominant isoform in both groups, the ratio of 121/165 was 13 
significantly higher in the group with missense TP53 mutations (Figure 5F). A higher 121/165 ratio 14 
was also detected in ID4-high compared with ID4-low tumors in the group with missense TP53 15 
mutations. 16 
 17 
Mutant p53 and ID4 favor interaction of MALAT1 with VEGFA precursor mRNA. To 18 
evaluate whether the identified RNP complex directly participates in control of VEGFA isoforms 19 
expression, we analyzed whether its mutant p53 component is recruited to VEGFA genomic 20 
regions.  21 
Though no longer able to bind the consensus sequences of wt-p53, the mutant p53 proteins have 22 
been shown extensively to control their targets by tying their genomic regions to interaction with 23 
other DNA-binding proteins [41].  24 
Chromatin Immunoprecipitation (ChIP) analysis detected mutant p53 protein on the two analyzed 25 
genomic regions of the VEGFA gene in MDA-MB-468 cells (Figure 6A-B) but no significant 26 
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enrichment was found on a negative control region (NC). The highest mutant p53 enrichment was 1 
detected on the boundary between intron 7 and exon 8 (Figure 6A-B) of VEGFA gene. Analysis of 2 
mutant p53 binding to VEGFA pre-mRNA through RIP performed under crosslinking conditions 3 
evidenced a significant enrichment for mutant p53 at the boundary between intron 7 and exon 8 4 
(Figure 6C) indicating that mutant p53 is in the right place to influence recruitment of splicing 5 
factors to the transcription complex as it transcribes the DNA.  6 
We next evaluated whether the MALAT1 lncRNA interacts with VEGFA pre-mRNA. MALAT1 7 
has been shown to interact with target pre-mRNAs preferentially in intronic regions [53]; 8 
interestingly, bioinformatics analysis predicted the existence of four RNA:RNA interacting regions 9 
between VEGFA intron 7 and MALAT1 (detailed in Appendix Figure S2A). Recovery of 10 
MALAT1-bound RNAs by ChIRP assay revealed that it interacted with VEGFA pre-mRNA in 11 
MDA-MB-468 (Figure 6D, si-SCR) and SKBR3 (Appendix Figure S2B) cells. Of note, depletion of 12 
ID4 or mutant p53 impaired MALAT1-preVEGFA interaction (Figure 6D and Appendix Figure 13 
S2B).  14 
SRSF1 has previously been shown to control VEGFA pre-mRNA splicing by binding to a short 15 
sequence upstream of the proximal splice site of exon 8 [24]; RIP analysis in control and MALAT1-16 
depleted MDA-MB-468 cells showed that SRSF1 recruitment on VEGFA pre-mRNA was 17 
decreased by 40% in absence of MALAT1 (Figure 6E and Appendix Figure S2C). Binding of 18 
SRSF1 to mature VEGFA mRNA was also impaired by 60% (Figure 6F) after MALAT1 depletion. 19 
Altogether these results indicate that mutant p53 and ID4 proteins enable interaction of MALAT1 20 
with VEGFA pre-mRNA, finally stabilizing binding of SRSF1 to this precursor. 21 
 22 
Mutant p53, ID4, SRSF1 and MALAT1 expression in breast cancer cells favors angiogenesis 23 
through repression of VEGF165b. As the balance between the pro- and anti-angiogenic isoforms of 24 
VEGFA is a major determinant of tumour angiogenesis, we evaluated whether depletion of the 25 
various components of the ribonucleoprotein complex that we found to repress VEGFAxxxb 
14 
 
impacted the angiogenic potential of breast cancer cells. 1 
To verify that VEGFAxxxb isoforms have inhibitory activity on angiogenesis in breast cancer cells, 2 
similarly to that reported for other experimental systems [35, 36] we tested the activity of 3 
VEGFA165 and VEGFA165b in a tube formation assay. Serum-free media with or without 4 
recombinant VEGF were used as controls (Figure 7A). As shown in Figure 7A and Appendix 5 
Figure S3A-B, conditioned medium (CM) from SKBR3 cells transfected with an expression vector 6 
for VEGFA165 caused a significant increase in the number of meshes formed by HUVEC-derived 7 
EA.hy926 endothelial cells, compared to control CM (CTR). In contrast, CM from SKBR3 cells 8 
transfected with the expression vector for VEGFA165b did not affect basal angiogenic potential, but 9 
was able to efficiently abrogate the angiogenic gain conferred by CM from VEGFA165 expressing 10 
cells (VEGFA165+VEGFA165b). Because we had observed that VEGFA165b exerts an inhibitory 11 
activity on the angiogenic potential of breast cancer cells, we expected that the depletion of mutant 12 
p53 or ID4, as well as the depletion of SRSF1 or MALAT1, leading to VEGFAxxxb upregulation, 13 
would result in a reduced angiogenic potential of breast cancer cells. To test this hypothesis, we 14 
performed tube formation assays involving the growth of endothelial cells in the presence of CM 15 
either from control SKBR3 cells (si-SCR) or cells depleted of mutant p53, ID4, SRSF1 or 16 
MALAT1. As shown in Figure 7B and Appendix Figure S3B, all four interference conditions 17 
significantly reduced the angiogenic potential of SKBR3 cells, as assessed by counting the number 18 
of meshes formed by endothelial cells. To check whether this reduced angiogenic potential was 19 
VEGFA-dependent, we tested CM from siRNA-transfected SKBR3 cells, supplemented with 20 
recombinant VEGFA protein (rhVEGFA). rhVEGFA did not affect tube formation in control si-21 
SCR condition but led to partial recovery of angiogenic potential in the various interference 22 
conditions (Figure 7C). Of note, a complete recovery of tube formation potential was observed 23 
when VEGFA165b blocking antibody was also added to the CM (Figure 7C and Appendix Figure 24 
S3C), indicating the existence of an inhibitory activity by VEGFA165b in CM from siRNA treated 25 
cells.  26 
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VEGFA signature expression is enriched in basal-like breast cancers showing mutant p53 and 1 
high ID4 levels. We next aimed to explore whether mutant p53 and ID4 expression is relevant for 2 
VEGFA signaling control in human breast cancer. As VEGFAxxxb isoforms inhibit VEGFA-3 
dependent signal transduction [33], we expected that VEGFA signaling would be strongly activated 4 
in cancer cells expressing high levels of ID4 and carrying a mutant p53 protein. 5 
To test VEGFA signaling activity, we first created a VEGFA signature by selecting genes that have 6 
been reported and validated in the literature to be directly activated by the VEGFA-dependent 7 
signaling pathway (16-genes VEGFA signature, indicated as “16-VEGFA”, Appendix Table S3). 8 
We then evaluated the expression of the 16-VEGFA signature using a collection of gene expression 9 
data from basal-like breast cancers (BLBC) of the Metabric cohort. BLBC is characterized by the 10 
highest incidence of TP53 gene mutations among all breast cancer subtypes, with 80% of patients 11 
carrying TP53 mutations (half of which are missense mutations) [54]. Of note, high ID4 expression 12 
is inversely related to survival specifically in this breast cancer subtype [47, 48].  13 
We then evaluated the expression of the 16-VEGFA signature, as well as of other VEGFA 14 
signatures from the MSigDB database (http://software.broadinstitute.org/gsea/msigdb/), in relation 15 
to ID4 expression levels, performing gene-set enrichment analysis (GSEA) on tumors with different 16 
TP53 status. As shown in Figure 8A-B, the 16-VEGFA and two additional signatures were 17 
significantly enriched in high-ID4 vs low-ID4 expressing tumors specifically in the mutant p53 18 
group. No significant correlation was evidenced in the wt-p53 group or in tumors presenting TP53 19 
deletion (ko-p53) (Figure 8A). As SRSF1 is predominantly controlled by post-translational 20 
modifications and MALAT1 by intranuclear localization, we couldn’t consider their expression 21 
levels for GSEA analysis. 22 
The 16-VEGFA signature was also tested comparing high-ID4 vs low-ID4 expressing tumors in a 23 
second cohort of BLBCs (the Breast Cancer Compendium Cohort, Appendix Table S4 [55]). 16-24 
VEGFA signature was significantly enriched in high-ID4 tumors (FDR=0.024), with a subset of 25 
particularly enriched genes, which constitute the so-called “core” (MMP1, COX-2, DSCR1, EGR1, 26 
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FLT1, ESM1, CD55).  1 
As both ID4 and VEGFA have been reported to impact survival in breast cancer, we evaluated 2 
whether ID4 and VEGFA signature cooperate in survival prediction in BLBC. As expected ID4, as 3 
well as VEGF signature and VEGF “core” signature associate with survival in the Breast Cancer 4 
Compendium Cohort (Figure 8D-E, Figure EV5A-B). Combination of information about expression 5 
levels of ID4 and VEGFA signature evidenced that tumors with high-ID4/high-VEGFA signature 6 
are associated with a significantly lower survival compared to low-ID4/low-VEGFA signature (HR 7 
= 3.13, 95% CI (1.27-7.68), log-rank test P= 0.0085) (Figure 8D and Figure EV5C). The remaining 8 
combinations (high-ID4/low-VEGFA signature, low-ID4/high-VEGFA signature) showed an 9 
intermediate behavior. A similar but more significant result was obtained considering the 10 
combination of ID4 and the VEGFA “core” signature (HR = 4.61, 95% CI (1.79-11.88), log-rank 11 
test P = 0.0004) (Figure 8F).  12 
Altogether, these data indicate that high expression of ID4 correlates with strongly activated 13 
VEGFA signaling specifically in tumors carrying missense TP53 mutation. Moreover, the 14 
combination of ID4 and VEGFA signature expressions robustly predicts the clinical outcome of 15 
these tumors. 16 
 17 
DISCUSSION 18 
In this study, we demonstrated that mutant p53 and ID4 proteins are able to form a complex with 19 
the splicing factor SRSF1 in the presence of MALAT1 lncRNA in breast cancer cells. The 20 
expression of all these components is required for the formation of this ribonucleoprotein complex. 21 
It is possible that additional proteins participate to the formation of these complexes and this will be 22 
clarified by further studies including in vitro assays to evaluate direct protein:protein interactions. 23 
The expression of mutant p53 and ID4 was related to the delocalization of MALAT1 from nuclear 24 
speckles. This suggests that the protein complex ID4-mutant p53-SRSF1 may cover the MALAT1 25 
speckle localization sequence and thereby relocate it out of speckles. Alternatively, it is also 26 
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possible that mutant p53 and ID4 control the expression of proteins required for the localization of 1 
MALAT1 to speckles, for example, RNPS1, SRm160 and IBP160 [11], although the direct 2 
interaction between the three proteins and MALAT1 argue against this being required.  3 
Our results also indicate that mutant p53 and ID4 expression directs MALAT1 to chromatin regions 4 
that contain histone H3. It is possible that this makes MALAT1 more available at sites of active 5 
transcription/splicing on the chromatin. We indeed found a higher level of interaction of MALAT1 6 
with histone H3 (exclusively localized in chromatin) and a lower level of interaction of MALAT1 7 
with U2 snRNA (typically localized in nuclear speckles) in cells expressing mutant p53 and ID4, 8 
compared to cells depleted of mutant p53 or ID4.   9 
SRSF1 activity is modulated by phosphorylation events [23, 56]. Specifically, hypophosphorylated 10 
SRSF1 is enriched in the cytoplasmic compartment where it favors translation of its target mRNAs. 11 
The SRPK splicing factor kinases are responsible for SRSF1 phosphorylation in the cytoplasm, 12 
leading to its nuclear translocation and accumulation in nuclear speckles. There, a family of Cdc2-13 
like nuclear kinases (Clk kinases), as well as SRPKs, act on already-phosphorylated SRSF1, leading 14 
to its hyperphosphorylation, which causes its release from speckles to areas where the splicing 15 
reaction takes place [23]. Further investigation will enable the deciphering of whether the binding 16 
of mutant p53 and ID4 to SRSF1 is responsible for the modulation of phosphorylation events, thus 17 
influencing the interaction between SRSF1 and MALAT1. 18 
SRSF1 has been reported to promote PSS selection in terminal exon choice during splicing of the 19 
VEGFA mRNA, thus favoring the production of pro-angiogenic isoforms at the expense of anti-20 
angiogenic isoforms. Accordingly, we observed that ID4 and mutant p53 proteins, which promote 21 
stabilization of the binding of SRSF1 to MALAT1, inhibit the production of anti-angiogenic 22 
VEGFAxxxb isoforms and increase the VEGFA 121/165 isoforms ratio. Repression of VEGFAxxxb 23 
has been previously shown in various malignancies including melanoma, and renal and colorectal 24 
carcinoma. However, the molecular mechanism governing the switch from the anti-angiogenic 25 
VEGFA isoforms, which are predominant in non-transformed cells, to the pro-angiogenic ones, 26 
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which are the most expressed in cancer cells, has yet to be exhaustively deciphered. We show here 1 
that in breast cancer cells, a mechanism promoting the repression of VEGFAxxxb forms relies on the 2 
formation of the quaternary complex containing SRSF1 and MALAT1, previously characterized to 3 
interact, and the ID4 and mutant p53 proteins, these being ultimately required for the formation of a 4 
stable RNP complex. The depletion of individual components of the RNP complex, is sufficient to 5 
release the expression of VEGFAxxxb isoforms and to reduce the angiogenic potential of breast 6 
cancer cells. Interestingly, MALAT1 has been recently shown to promote angiogenesis driven by 7 
neuroblastoma cells through its ability to modulate FGF2 expression [57]. 8 
VEGFAxxxb isoforms expression has been related to the inhibition of VEGFR2 signaling. 9 
Accordingly, we observed enrichment for VEGFA signatures expression in breast tumors 10 
characterized by the presence of a missense mutation in TP53 gene and high ID4 expression. 11 
Further investigation, focused on the examination of phosphorylation status of SRSF1 and 12 
intranuclear localization of MALAT1, in breast cancer sections, will allow the analysis of their 13 
association with TP53 status, ID4, VEGFA signature expression and survival. 14 
In aggregate our findings discover a novel mechanistic layer through which gain of function mutant 15 
p53 proteins enhance angiogenesis. Thus, the disassembling of the ribonucleoprotein complex 16 
comprising mutant p53/ID4/ SRSF1/MALAT1 might hold therapeutic premise for mutant p53 17 
breast cancers. 18 
 19 
MATERIALS AND METHODS 20 
Cell lines, siRNA and plasmid transfections, and retroviral infections  21 
All cell lines were grown at 37˚C, 5% CO2, in medium containing 10% fetal bovine serum (FBS) 22 
and penicillin/streptomycin. SKBR3 (ATCC) were grown in McCoy’s 5A medium, MDA-MB-468 23 
(ATCC) in DMEM F12 medium, MDA-MB-231 (ATCC), MCF7 (ATCC) and H1299 (ATCC) in 24 
RPMI medium, HEK T293 cells in DMEM AQ medium. OVCAR-3 (ATCC) were grown in RPMI 25 
medium with 20% fetal bovine serum (FBS) plus 0.01 mg/ml bovine insulin and 26 
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penicillin/streptomycin. Stable cell lines SKBR3 and MDA-MB-468 (sh-p53 and wt-p53) were 1 
obtained by lentiviral transduction. The system is composed of a vector containing both shRNA 2 
targeting endogenous mutant p53 and a sequence encoding wild type p53. The sequence coding for 3 
wt-p53 possesses silent mutations in a region recognized by shRNA. shRNA binding site: GAC 4 
TCC AGT GGT AAT CTA C (shRNA sequence); modified p53 sequence: GAC TCG AGC GGC 5 
AAC CTC C. Substituted nucleotides are underlined.  6 
For si-RNA transfection, the GenMute siRNA&DNA (Signagen) transfection reagent or RNAiMax 7 
(Thermofisher) were used following manufacturer’s instructions. List of siRNAs used in the study 8 
is enclosed in Appendix Table S5. 9 
 10 
Western blot 11 
For the western blot analysis, cells were lysed in RIPA buffer. The protein concentration was 12 
measured using a BCA protein assay kit (Thermo Scientific). The lysate was mixed with 4x 13 
Laemmli buffer. Total protein extracts were resolved on polyacrylamide gel and then transferred 14 
onto nitrocellulose membrane. The following primary antibodies were used: DO-1 and CM-1 (anti-15 
p53, kind gift from B.Vojtesek), A96 (anti-SRSF1, Santa Cruz), H70 and B-5 (anti-ID4, Santa 16 
Cruz), M106 (anti-ID4, CalBioreagents), ab46154 (anti-VEGFA, Abcam), ab14994 (anti-17 
VEGFA165b, Abcam), and ab16047 (anti-laminB1, Abcam), E2F1 (Santa Cruz), H3 and modified 18 
H3 forms (Abcam). For detection, two types of secondary antibodies were used: antibodies fused 19 
with HRP for chemiluminescence detection, or goat-anti-mouse-800 and goat-anti-rabbit-680 20 
LicorOdyssay antibodies for detection with an infrared scanner. 21 
 22 
RNA Fluorescence In Situ Hybridization (FISH) 23 
To study the subcellular localization of MALAT1, Fluorescence In Situ Hybridization was 24 
performed using a mixture of 48 fluorescent (Quasar® 570) StellarisTM RNA probes (Biosearch 25 
Technologies, Inc.) distributed evenly along the MALAT1 RNA. Cells were fixed with 3.7% 26 
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formaldehyde in PBS and permeabilized with 70% ethanol for at least 24 h. Then, the 1 
manufacturer's protocol was followed. Staining was visualized with a fluorescence microscope and 2 
patterns of MALAT1 distribution (speckled or diffused plus speckled) were counted manually using 3 
ImageJ software. Microscope images evaluation was performed independently and in blinded 4 
manner by two investigators. 5 
 6 
Combined Immunofluoresce-RNA FISH 7 
Cells were fixed using 3% paraformaldehyde (PFA) for 10 min at RT, permeabilized with 0.25% 8 
v/v Triton X-100 in PBS for 8min, blocked 20min in PBS/1% w/v BSA and incubated with primary 9 
anti-p53 1:250 (FL393, Santa Cruz). Secondary antibody (AlexaFluor488, 1:500) was incubated for 10 
40min. Cells were post-fixed using 3% PFA for 10 min at RT and subjected to RNA FISH as 11 
described above. Fluorescence high-resolution images of fixed cells, labelled with DAPI (cell 12 
nuclei), AlexaFluor 488 (p53 protein) and Quasar 570 (MALAT1 RNA) were acquired through an 13 
inverted Olympus IX83 microscope (Olympus Europe, Hamburg, Germany), equipped with an 14 
UPLSAPO 60X water immersion objective (NA 1.2) with a confocal aperture of 600 microns, for a 15 
theoretical optical resolution of 210 nm (horizontal) and 3.8 microns (vertical). The PMT voltages 16 
were adjusted such that no pixels were saturated in the image. Colocalization analysis between 17 
green and red channels was completed following a well-established protocol. Per each field-of-18 
view, the DAPI channel was used to identify ROIs selecting the nuclei portion of the image. Each 19 
ROI, then, was analysed to determine relevant statistical parameters (Pearson’s correlation 20 
coefficient R [58], Manders colocalization coefficient M1 and M2 (Manders, E. M. M., F. J. 21 
Verbeek, and J. A. Aten. 1993. Measurement of colocalization of objects in dual-color confocal 22 
images. J. Microsc. 169:375–382), and Li intensity correlation quotient ICQ [59], by an automatic 23 
threshold procedure [60]. The average results from all the ROIs for each sample are reported in 24 
Fig.1E.  25 
 26 
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Proximity ligation assay and immunofluorescence 1 
To study protein-protein interactions in a quantitative manner, the Duolink® proximity ligation 2 
assay (PLA) was used (Sigma-Aldrich). Cells cultured on a cover glass were fixed in 3.7% 3 
formaldehyde in PBS, permeabilised for 10 min with 0.25% Triton X-100 in PBS, and blocked for 4 
30 min with Duolink blocking buffer. Further, the manufacturer protocol was followed. The nuclei 5 
were stained with DAPI. ImageJ software was used to count the positive signals. The samples for 6 
immunofluorescence were prepared in the same way as for PLA. Microscope images evaluation 7 
was performed independently and in blinded manner by two investigators. 8 
 9 
RNA isolation and RT-qPCR 10 
The RNA was isolated with Trizol (Sigma) and its concentration was measured using a NanoDrop 11 
2000 (Nanodrop Technologies, Wilmington, DE, USA). Reverse transcription was performed with 12 
SuperScript II or MMLV-RT (Invitrogen). qPCR was carried out on ABI PRISM 7500 Fast 13 
Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Primers used for PCR 14 
analyses are listed in Appendix Table S5. The expression values of mRNAs were calculated by 15 
standard curve method and normalized over the indicated housekeeping control genes. P‐values 16 
were calculated with two‐tailed Student's t‐test. Statistically significant results were referred with a 17 
P‐value < 0.05. 18 
 19 
Co-immunoprecipitation 20 
The cells were lysed in buffer composed of 50 mM HEPES pH 7.4, 160mM NaCl, 10mM MgCl2, 21 
5mM KCl, 2 mM EDTA pH 8.0, 1mM DTT, 0,5% Triton X100 and protease and phosphatase 22 
inhibitors. 1 mg of total protein lysate was used for immunoprecipitation with Dynabeads® 23 
(Invitrogen). After immunoprecipitation, the beads were boiled with Laemmli buffer supplemented 24 
with 1 mM DTT. The immunoprecipitated proteins were analyzed by western blot. 25 
 26 
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RNA Immunoprecipitation (RIP) on native lysates and RIP-chip 1 
The Dynabeads® (Invitrogen) were preincubated with antibodies specific to the target protein for 2 
24 h at 4ºC in NT2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40). 3 
The following antibodies were used: DO1 (Santa Cruz) and Ab7 (Calbiochem) for p53 IP; H70 4 
(Santa Cruz) and ab49261 (Abcam) for ID4 IP; sc-33652 SF2/ASF (96) (Santa Cruz) for SRSF1 IP. 5 
To obtain native lysates cells were trypsinized, pelleted and lysed in PLB buffer (10 mM HEPES 6 
pH 7.0, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40, 25 mM EDTA pH 8.0, 1 mM DTT, 100 U/ml 7 
RnaseOUT, and protease and phosphatase inhibitors). For every sample, antibody-coated beads 8 
were suspended in 850 µl of NET buffer (850 µl NT2 supplemented with 10 µl of 100 mM DTT, 30 9 
µl of 0.5 M EDTA and 5 µl of RnaseOUT). 1 mg of total protein lysate in 100 µl PLB was added to 10 
the beads and incubated for 1 h at room temperature. After immunoprecipitation, beads were 11 
washed 4 times with 1 ml of ice cold NT2 buffer, then resuspended in 100 µl of NET buffer plus 12 
100 µl of Proteinase K buffer (200 mM Tris-HCl pH 7.5, 20 mM EDTA pH 8.0, and 100 mM NaCl, 13 
2% SDS). Samples were incubated with 30 µg of Proteinase K for 30 min at 55°C. RNA was 14 
isolated from the supernatant with Trizol (Sigma) according to manufacturer protocol. The obtained 15 
cDNA was further analyzed by real-time PCR. Enrichments were normalized over GAPDH and/or 16 
RPL19 expression.  17 
RNA obtained from RIP experiments was subjected to gene expression profiling using the 18 
Affymetrix platform (Human Gene 1.0 ST arrays) according to the manufacturer's instructions.  19 
Scanned image files (.CEL) were processed, normalized (RMA-Sketch Quantile) and Log2-20 
transformed using Affymetrix Expression Console. Transcripts with an expression value lower than 21 
6 were filtered out and not considered for further analyses. Transcripts significantly enriched in 22 
samples immunoprecipitated in presence of anti-ID4 antibodies (H-70 from Santa Cruz and 23 
ab49261 from Abcam) as compared to IgG negative controls were selected using the supervised 24 
comparison analysis of the Analyzer software [61]. Specifically, transcripts enriched more than 2.5-25 
fold with both antibodies, when compared to IgG negative control, were used for subsequent 26 
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analysis.  1 
 2 
RNA Immunoprecipitation (RIP) on lysates from crosslinked cells 3 
Cells were crosslinked with 254 nm-U.V. light 800 mJ/cm2 (using 10-cm dish with 2.5mL PBS) or 4 
with formaldehyde (F.A.) solution (50 mM Hepes-KOH pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 5 
mM EGTA, 11% Formaldehyde, ddH2O) 1% final concentration 10 min RT. Nuclei were isolated 6 
and resuspended in Lysis Buffer (Tris-HCl pH7.5 50mM, EDTA 1mM, SDS 0.5%, DTT 1mM), 7 
using 200 µL for each planned IP sample, and sonicated to obtain a smear not higher than 500bp. 8 
Lysate was treated with DNase (DNAfree, Ambion) and diluted with 400µL of Correction Buffer 9 
(NP-40, 0.625%, DOC, 0.312 %, MgCl2, 5.6 mM, Tris-HCl pH7.5, 47.5 mM, NaCl, 187.5 mM, 10 
Glycerol, 12.5 %, DTT 1 mM). IP was carried out over night at +4°C. For histone H3 IP the 11 
following ChIP-grade antibodies from Abcam were employed:  ab1791 (H3); ab4729 (H3K27Ac); 12 
ab9050 (H3K36me3). IP washing and proteinase K digestion were carried out as above, 13 
crosslinking was reversed by incubation at 70°C for 30 min and RNA was recovered by TRIzol 14 
extraction. 15 
 16 
ChIRP 17 
ChIRP was performed as described [49]. 20 million cells were used for each condition. The 18 
oligonucleotides used for MALAT1 immunoprecipitation are listed in Appendix Table S5. 19 
Biotinylated oligonucleotides were recovered using Dynabeads® MyOne™ Streptavidin C1 20 
(Invitrogen). After the washing steps, 60% of the recovered material was used for protein 21 
purification, 20% for RNA purification, and 20% for DNA purification. Proteins abundance was 22 
evaluated by dot blot analysis. Specifically, half of volume of the recovered proteins was loaded in 23 
the wells of a Bio-Dot apparatus (Biorad), then transferred to the nitrocellulose membrane and used 24 
for blotting using antibodies directed against SRSF1 (A96, Santa Cruz) or histone H3 (Abcam). 25 
 26 
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Chromatin Immunoprecipitation (ChIP) 1 
Formaldehyde cross-linking and chromatin immunoprecipitation were performed as previously 2 
described [38]. The chromatin solution was immunoprecipitated with sheep anti-p53 serum (Ab7, 3 
Calbiochem), anti-p53 (Santa Cruz, sc-6243), or IgG as negative control. Cyclin B1 first intron was 4 
amplified as negative control region as described [62]. P‐values were calculated with two‐tailed t‐5 
test. Statistically significant results were referred with P‐value < 0.05. 6 
 7 
Tube formation assay  8 
To perform the tube formation assay, we used the EA.hy926 cell line, a hybridoma of HUVEC and 9 
A549 cell lines. EA.hy926 cells were infected with a lentiviral vector constitutively expressing 10 
dtTomato fluorescent protein. Before the experiment, 80%-confluent cells were starved for 24 h in 11 
serum-free medium (SFM). Experiments were performed on 96-well µ-slides for angiogenesis 12 
(Ibidi) coated with 10 µl/well Growth Factor Reduced Matrigel (BD). After Matrigel gelation, 35 µl 13 
of conditioned medium (CM) was added. CM was obtained by cultivation of cancer cells for 48 h in 14 
a medium with 1% FBS. As a positive control, 100 ng/ml of recombinant human VEGFA165 15 
(PeproTech) was used. Fresh medium with 1% FBS served as a negative control. Then, 35 µl of 16 
cells suspended in SFM was added to a final density of 11000 cells/well. Cell suspension was 17 
supplemented with recombinant human VEGF165 (PeproTech, rhVEGF, 20ng/ml) or anti-18 
VEGF165b antibody (ab14994, Abcam, 25nM) and rhVEGF together. Pictures were taken after 8h 19 
on a wide-field fluorescence microscope. Image analysis was performed using the ImageJ plugin for 20 
angiogenic assays. 21 
 22 
Collection and processing of breast cancer gene expression data  23 
The breast cancer compendium was generated as described [55]. Briefly, we started from a 24 
collection of 4640 samples from 27 major datasets comprising microarray data of breast cancer 25 
samples annotated with histological tumour grade and clinical outcome. The PAM50 classifier for 26 
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the identification of breast cancer molecular sub-types [63] encoded in the genefu R package [64] 1 
classified 751 breast cancer samples as basal, of which 201 presented follow-up information.  2 
The METABRIC dataset was downloaded from the European Genome‐Phenome Archive (EGA, 3 
http://www.ebi.ac.uk/ega/) under accession number EGAD00010000210 [65]. The dataset 4 
comprises microarray data and clinical annotations for 997 breast cancer samples, of which 118 5 
were annotated as basal using PAM50. The status of TP53 was derived from Dataset EV1 of 6 
Silwal‐Pandit and colleagues [66] and merging molecular sub-typing and TP53 status returned 35 7 
“missense” mutant p53, 22 wt‐p53 and 30 ko-p53 basal breast cancer samples. 8 
VEGFA isoforms level in breast cancer patients were analyzed using the RNAseq data of the 9 
TCGA Breast Invasive Carcinoma Dataset [54, 67] comprising 672 “missense” mutant p53 and 173 10 
wt-p53 samples. RNAseq data were downloaded from the Firehose Broad GDAC website 11 
(http://gdac.broadinstitute.org/) selecting signals normalized at isoform level. 12 
Survival analysis 13 
Basal tumors in breast cancer compendium were classified as “Low ID4 expression” or “High ID4 14 
expression” by considering the expression of the 209291_at Affymetrix probeset representing ID4 15 
and using the median expression value in the cohort as the threshold. To identify two groups of 16 
tumors with either high or low VEGFA signature we used a classification rule based on the VEGFA 17 
signature score, calculated by summarizing the standardized expression levels of the genes in the 18 
signature into a combined score with zero mean. Tumors were classified as "VEGFA signature 19 
Low” if the combined score was negative and as "VEGFA signature High” if the combined score 20 
was positive. The same rule was applied with the VEGFA core signature. To evaluate the 21 
prognostic value of the signatures, we estimated the patients’ survival probability using the Kaplan-22 
Meier method. The Kaplan-Meier curves were compared using the log-rank (Mantel-Cox) test and 23 
P-values were calculated according to the standard normal asymptotic distribution. Cox 24 
proportional hazards models were constructed to estimate the Hazard Ratios. 25 
Over-representation analysis 26 
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Gene Set Enrichment Analysis (GSEA) was used to investigate whether high ID4 expression was 1 
associated with elevated activity of VEGFA signaling pathway. GSEA software 2 
(http://www.broadinstitute.org/gsea/index.jsp) was applied on log2 expression data of basal tumors 3 
classified as “High ID4 expression” or as “Low ID4 expression”. GSEA returned the VEGFA 4 
signature as up-regulated in phenotype “High ID4 expression” (Enrichment Score ES>0) and 5 
significantly enriched at FDR<5% when using 1,000 permutations of gene sets.  6 
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Figure 1. ID4 and mutant p53 proteins bind to MALAT1 lncRNA in SRSF1-dependent manner.  1 
A-C. RIP (Ribonucleoprotein ImmunoPrecipitation) assays performed in SKBR3 and MDA-MB-2 
468 breast cancer cells using antibodies directed to ID4 or p53. IgG was used as negative control. 3 
Native lysates or lysates from cells crosslinked with formaldehyde (F.A.) or U.V. light were 4 
employed. RT-qPCR of MALAT1 RNA and control mRNAs (GAPDH, RPL19) is shown. Relative 5 
enrichment represents enrichment of each transcript in ID4-IP o p53-IP over control IgG-IP sample. 6 
D. Fluorescence high-resolution images of fixed cells, labelled with DAPI (cell nuclei), AlexaFluor 7 
488 (p53 protein) and Quasar 570 (MALAT1 RNA). Merged images of AlexaFluor 488 and Quasar 8 
570 signals are shown. Scale bars, 10µm. E. Pearson’s correlation coefficient R, Manders 9 
correlation coefficient M2 (tM2) and Li intensity correlation quotient ICQ (Li) were considered to 10 
estimate colocalization between p53 protein and MALAT1 RNA from combined IF-FISH assays in 11 
the indicated cell lines. 12 
F. RIP assays performed in MDA-MB-468 cells using an antibody directed to SRSF1 (A96, Santa 13 
Cruz). MALAT1 and NEAT1 (negative control) RNA abundance was evaluated by RT-qPCR. G-14 
H. RIP assays of ID4 and p53 performed in MDA-MB-468 cells depleted or not of SRSF1 15 
expression using two siRNAs. SRSF1, ID4, p53 proteins and MALAT1 RNA levels following 16 
siRNA transfection are shown in (G).  17 
Data are presented as mean ± SEM. *P≤0.05, **P≤0.005, ***P≤0.005 (two-tailed Student's t-test). 18 
Results from at least three biological replicates are shown. 19 
 20 
Figure 2. SRSF1 interacts with mutant p53 and ID4 proteins in a MALAT1-dependent manner. 21 
A-C. Proximity Ligation Assays (PLA) of SRSF1-mutant p53 (A) SRSF1-ID4 (B), and mutant p53-22 
ID4 (C) interactions in MDA-MB-468 cells depleted (si-MALAT1) or not (si-SCR) of MALAT1 23 
RNA expression using two different siRNAs. Box plots represent the number of interactions 24 
detected per nucleus. D-E. Western blot (D) and RT-qPCR (E) analysis of MDA-MB-468 cells 25 
depleted of MALAT1 RNA expression using two different siRNAs.  F-G. PLA of SRSF1-p53 26 
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interaction in parental MDA-MB-468 cells (indicated as R273H) as well as in cells stably depleted 1 
of endogenous mutant p53R273H expression (indicated as sh-p53). Immnunofluorescence (F) 2 
represents p53 staining, DAPI (cell nuclei), PLA signals (SRSF1-p53 interactions) and merged 3 
signals DAPI/PLA. Box plot (G) represents the number of SRSF1-p53 interactions detected per 4 
nucleus. H. H1299 cells transfected with mutant p53R273H vector or an empty vector as control 5 
were used to evaluate: SRSF1-p53 interaction (H) by immunoprecipitation of SRSF1 (and IgG as 6 
control) followed by western blot of p53, ID4-p53R273H (I) and ID4-SRSF1 (I) interactions by 7 
immunoprecipitation of ID4 followed by western blot of p53 and SRSF1, respectively. J. SRSF1-8 
p53 interaction evaluated in SKBR3 cell lysate, treated or not with RNaseA, by 9 
immunoprecipitation of SRSF1 (and IgG as control) followed by western blot of p53. 10 
*P≤0.05, **P≤0.005, ***P≤0.005 (two-tailed Student's t-test). n.s: not significant. Results from at 11 
least three biological replicates are shown. 12 
 13 
Figure 3. ID4 and mutant p53 proteins stabilize binding of splicing factor SRSF1 to MALAT1 14 
lncRNA.  15 
 A-B. p53, ID4, SRSF1 proteins and MALAT1 RNA levels evaluated by Western blot (A) and RT-16 
qPCR (B) analyses in MDA-MB-468 cells depleted or not of p53R273H or ID4 expression using 17 
two different siRNAs for each factor. C. RIP assays performed in MDA-MB-468 cells, depleted or 18 
not of ID4 or mutant p53R273H expression, using an antibody directed to SRSF1 (A96, Santa 19 
Cruz). MALAT1 RNA abundance was evaluated by RT-qPCR and normalized over GAPDH 20 
mRNA. D. RIP assay performed in control and ID4-depleted MDA-MB-468 cells crosslinked with 21 
formaldehyde using an antibody directed to SRSF1 (A96, Santa Cruz). Recruitment of SRSF1 along 22 
MALAT1 RNA was evaluated by using 14 couples of primers covering the whole MALAT1 RNA. 23 
Numbers indicate the nucleotide positions on MALAT1 RNA of the couples of primers used. E. 24 
PLA assay showing the number of interactions between SRFS1 and p53 protein per nucleus, in 25 
control and ID4-depleted cells. F. Western blot showing ID4 and mutant p53 protein levels in 26 
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MDA-MB-468 cells transfected with the indicated siRNAs and used for ChIRP assays. G-H. 1 
ChIRP assay showing the recovery of MALAT1 RNA (G) and its associated SRSF1 protein amount 2 
(H) by using a set of biotinylated oligonucleotides complementary to MALAT1 RNA sequence 3 
(Bio-MALAT1), or a set of control oligonucleotides (Bio-CTR), in lysates from control (si-SCR), 4 
ID4-depleted (si-ID4) and mutant p53-depleted (si-p53) MDA-MB-468 cells. Enrichment for 5 
MALAT1 RNA was evaluated by RT-qPCR and normalized over GAPDH mRNA (G). Enrichment 6 
for SRSF1 protein was evaluated by dot-blot analysis (H). Quantification was performed by 7 
densitometry on a UVITEC instrument, subtracting background signal, and is presented as folds of 8 
Bio-MALAT1 signal over Bio-CTR signal in si-SCR sample. Data are presented as mean ± SEM. 9 
*P≤0.05, **P≤0.005 (two-tailed Student's t-test). 10 
 11 
Figure 4. ID4 and mutant p53 proteins control MALAT1 intranuclear distribution. A. RNA FISH 12 
was performed in control (si-SCR), mutant p53-depleted (si-p53) and ID4-depleted (si-ID4) SKBR3 13 
and MDA-MB-468 cells using StellarisTM fluorescent RNA probes (Biosearch Technologies, Inc.), 14 
spanning the whole MALAT1 lncRNA, and visualized at fluorescence microscope. Nuclei 15 
presenting speckled or diffused+speckled MALAT1 signal were counted, and the results are 16 
presented in graph (A). Differences in the intranuclear distribution of MALAT1 were evaluated by 17 
a two-tailed Student’s t-test. B. Images of cells presenting speckled localization of MALAT1 by 18 
RNA FISH analysis, as visualized by confocal microcopy. Merges of MALAT1 and DAPI signals 19 
are presented. Scale bars, 10µm.  C-F. ChIRP assay showing the recovery of MALAT1 RNA (C) 20 
and its associated histone H3 protein (D-E) by using a set of biotinylated oligonucleotides 21 
complementary to MALAT1 RNA sequence (Bio-MALAT1), or a set of control oligonucleotides 22 
(Bio-CTR), in lysates from control (si-SCR), ID4-depleted (si-ID4) and mutant p53-depleted (si-23 
p53) SKBR3 cells. Enrichment for MALAT1 RNA was evaluated by RT-qPCR and normalized 24 
over GAPDH mRNA (C). Enrichment for histone H3 protein was evaluated by dot-blot analysis (D-25 
E). Quantification was performed by densitometry on a UVITEC instrument, subtracting 26 
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background signal, and is presented as folds of Bio-MALAT1 signals over Bio-CTR signals (E). 1 
Binding of U2snRNA to MALAT1 in ChIRP was evaluated by RT-qPCR analysis; U2snRNA 2 
relative enrichment was obtained by normalization over 18S rRNA (F). G-J. RIP assay was 3 
performed in the indicated cell lines, depleted or not of mutant p53 and ID4 expression (panel G-H), 4 
after crosslinking with formaldehyde, using antibodies directed to histone H3 and its modified 5 
forms H3K36me3 and H3K27Ac and IgG as negative control (I-J). Binding to MALAT1 RNA was 6 
evaluated by RT-qPCR using six couples of primers spanning MALAT1 sequence. Box plots 7 
represent the distribution of the enrichment values of the six considered regions. Enrichment for 8 
each region is calculated as fold over the IgG negative control and is normalized over RPL19 9 
mRNA enrichment. *P≤0.05, **P≤0.005 (paired two-tailed Student's t-test).  10 
 11 
Figure 5. ID4, mutant p53, SRSF1 proteins and lncRNA MALAT1 modulate VEGFA isoforms 12 
expression. A. Schematic representation of the genomic organization of VEGFA gene exons 5-8 13 
and of the mRNAs obtained by their alternative splicing. B. RT-qPCR analysis of transcripts 14 
encoding pro- angiogenic (VEGFA165, VEGFA121) and anti-angiogenic (VEGFA165b, VEGFA121b) 15 
VEGFA isoforms in MDA-MB-468 cells after interference of mutant p53, ID4, SRSF1, MALAT1 16 
or hnRNP A1. Ratios of anti- vs pro-angiogenic isoforms are shown.  17 
C. Western blot analysis of total VEGFA and anti-angiogenic VEGFA165b proteins. Ratios of 18 
VEGFA165b in MDA-MB-468 and SKBR3 cells depleted of p53, ID4, SRSF1 or MALAT1 over si-19 
SCR sample, normalized to total VEGFA are shown.  20 
D. A representative western blot experiment of MDA-MB-468 cells. Numbers indicate ratio 21 
between VEGF165b protein densitometry values in interfered cells (si-p53, si-ID4, si-SRSF1, si-22 
MALAT1) over si-SCR sample normalized to total VEGFA protein levels.  23 
E. Ratio of the expression levels evaluated by RT-qPCR of isoform VEGFA121 over VEGFA165 in 24 
MDA-MB-468 cells after interference of mutant p53, ID4, SRSF1, MALAT1 or hnRNP A1. 25 
Data are presented as mean ± SEM. *P≤0.05, **P≤0.005, ***P≤0.0005, ****P≤0.00005  (Student's 26 
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t-test). Results from at least three biological replicates are shown. 1 
F. Ratio of the expression levels of isoform VEGFA121 over VEGFA165 obtained by analysis of 2 
RNAseq data from breast cancer samples (TCGA study). 10-90th percentile interval of the 3 
population is shown in whiskers. P-value was calculated by Wilcoxon signed-rank test.  4 
 5 
Figure 6. lncRNA MALAT1 interacts with VEGFA precursor transcript in ID4- and mutant p53-6 
dependent manner. A-B. Recruitment of mutant p53R273H protein on VEGFA genomic regions 7 
evaluated by chromatin immunoprecipitation (ChIP) in MDA-MB-468 cells. qPCR was performed 8 
using primers amplifying the regions indicated in panel A and a negative control region 9 
(NC=intronic region of cyclin B1 gene) previously reported [62]. C. Recruitment of mutant 10 
p53R273H protein on VEGFA precursor RNA evaluated by RIP in MDA-MB-468 cells crosslinked 11 
with formaldehyde. qPCR was performed using primers amplifying the regions indicated in panel 12 
A. 13 
D. ChIRP assay was performed to recover MALAT1 lncRNA and its associated RNAs by using a 14 
set of biotinylated oligonucleotides complementary to MALAT1 RNA sequence (Bio-MALAT1), 15 
or a set of control oligonucleotides (Bio-CTR), in lysates from control (si-SCR), ID4-depleted (si-16 
ID4) and mutant p53-depleted (si-p53) MDA-MB-468 cells. Enrichment for the indicated 17 
transcripts was evaluated by RT-PCR. Mature VEGFA mRNA was analyzed using primers 18 
recognizing all isoforms (reported in Appendix Table S5). E-F. RT-qPCR analysis of VEGFA 19 
precursor (E) and mature (F) RNAs performed on RIP experiments from control (si-SCR) and 20 
MALAT1-depleted (si-MALAT1) MDA-MB-468 cells immunoprecipitated using an antibody 21 
directed to SRSF1. Mature VEGFA mRNA was analyzed using primers recognizing all isoforms 22 
(reported in Appendix Table S5). 23 
*p<0.05; ***p<0.0005 (by Student’s t-test). 24 
 25 
Figure 7. ID4, mutant p53, SRSF1 and MALAT1 expression sustains the angiogenic potential of 26 
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breast cancer cells. A. Angiogenic tube formation assays performed by growing EA.hy926 1 
endothelial cells in the presence of serum-free medium with (100ng/mL) or without (0ng/mL) 2 
recombinant VEGF (rhVEGF), or conditioned medium (CM) from SKBR3 cells transfected with an 3 
empty vector (CTR), an expression vector for VEGFA165 (VEGF165) or an expression vector for 4 
VEGFA165b (VEGF165b). The endothelial cells were also tested with a mixture of CM from 5 
VEGFA165- and VEGFA165b-overexpressing SKBR3 cells. B. Angiogenic tube formation assays 6 
performed by growing EA.hy926 endothelial cells in the presence of CM from SKBR3 cells 7 
transfected with control siRNAs (si-SCR) or si-RNAs directed to ID4 (si-ID4), mutant p53 (si-p53), 8 
SRSF1 (si-SRSF1) or MALAT1 (si-MALAT1). Data are presented as mean ± SEM. **P≤0.0005, 9 
***P≤….., **** P≤ (Student's t-test). Meshes formed by EA.hy926 cells were counted from at least 10 
three biological replicates, each including three technical replicates.  11 
C. Angiogenic tube formation assays performed by growing EA.hy926 endothelial cells in the 12 
presence of conditioned medium (CM) from SKBR3 cells interfered as in (A) or plus recombinant 13 
VEGFA165 protein (rhVEGFA) alone or in combination with a blocking antibody recognizing 14 
VEGFA165b protein (Ab165b). *P≤0.05, **P≤0.01, ***P≤0.005 (Two-way ANOVA). Meshes 15 
formed by EA.hy926 cells were counted from at least three biological replicates, each including 16 
three technical replicates.  17 
 18 
Figure 8. VEGFA signature expression associates with ID4 expression in mutant p53-carrying 19 
basal-like breast cancers. A. Gene Set Enrichment Analysis (GSEA) of VEGFA-dependent 20 
signatures in ID4-high vs ID4-low basal-like breast cancers of the Metabric cohort with different 21 
TP53 status. NES, Normalized Enrichment Score; FDR, False Discovery Rate.  22 
B. Enrichment plot obtained through GSEA of the 16-VEGFA signature in ID4-high vs ID4-low 23 
basal-like breast cancer samples with mutated TP53 gene. C. Enrichment plot obtained through 24 
GSEA of 16-VEGFA signature in high-ID4 versus low-ID4 basal-like breast cancer samples from 25 
the Breast Cancer Compendium cohort. The black vertical bars indicate the positions of single 26 
36 
 
components of the VEGFA activity signature in the samples. The green line shows the cumulative 1 
score of the enrichment of the examined 16-VEGFA signature. A positive enrichment score 2 
indicates positive correlation between the 16-VEGFA signature and ID4 mRNA expression.  3 
D-F. Survival and Kaplan-Meier analyses performed on 201 basal-like breast cancer patients from 4 
the Breast Cancer Compendium cohort showing the predictive value on overall survival of the 5 
expression level of ID4 mRNA, VEGFA signatures and their combinations. Tumors were divided 6 
into high- or low-ID4 expression categories based on the median of ID4 expression in the series. 7 
 8 
 9 
EXPANDED VIEW FIGURE LEGENDS 10 
 11 
Figure EV1. A. RIP assays performed in OVCAR-3 cells using an antibody directed to p53. 12 
Relative enrichment is calculated as folds over IgG sample, normalized on RPL19 mRNA level. B. 13 
Fluorescence high-resolution images of fixed cells, labelled with DAPI (cell nuclei), AlexaFluor 14 
488 (p53 protein) and Quasar 570 (MALAT1 RNA). Merged images of AlexaFluor 488 and Quasar 15 
570 signals are shown. Scale bars, 10µm. C. Western blot analysis of wt-p53 and its phosphorylated 16 
form p-p53-Ser15 in the indicated cell lines with or without 8h treatment with 400nM Adriamycin. 17 
D. RT-qPCR analysis of MALAT1 RNA level in MCF10A and MCF7 cells treated or not with 18 
Adriamycin (ADR) as in (A). E. RIP assays performed in MCF10A and MCF7 cells treated or not 19 
with Adriamycin as in (A) were performed using antibodies directed to p53 and ID4 proteins. 20 
Relative enrichment is calculated as folds over IgG sample, normalized on RPL19 mRNA level. F. 21 
Fluorescence high-resolution images of the indicated fixed cell lines, labelled with DAPI (cell 22 
nuclei) and Quasar 570 (MALAT1 RNA). Scale bars, 10 µm. G. MALAT1 RNA abundance was 23 
evaluated by RT-qPCR in MDA-MB-468 cells depleted of SRSF1 using three different si-RNAs 24 
and normalized over GAPDH mRNA. Western blot on the left shows SRSF1 protein levels after si-25 
SRSF1-3 transfection, while SRSF1-1 and SRSF1-2 are shown in Figure 1G. 26 
37 
 
 1 
Figure EV2.  A-B. PLA assays showing interactions SRSF1-p53, SRSF1-ID4 and p53-ID4 in 2 
SKBR3 cells depleted or not of MALAT1 RNA expression using two different siRNAs (A). 3 
MALAT1 and ID4 level after MALAT1 interference was evaluated by RT-qPCR (B, graphs); p53 4 
and SRSF1 protein level after MALAT1 interference was evaluated by western blot (B, panels). C. 5 
Representative images of PLA experiments shown in Figure 2 C-E and Expanded Figure 2A. 6 
Merged signals of DAPI and PLA are shown in the indicated cells. D. PLA assays to evaluate the 7 
interaction between p53 and ID4 proteins, performed in the indicated control and SRSF1-depleted 8 
cell lines. E. Interaction between p53 and ID4 proteins was evaluated by immunoprecipitation of 9 
ID4 followed by western blot of p53 in the indicated cells, depleted or not of SRSF1 expression. 10 
 11 
Figure EV3. A. RIP assay performed in control and ID4-depleted MDA-MB-468 cells crosslinked 12 
with formaldehyde using an antibody directed to SRSF1 (A96, Santa Cruz). Enrichment of SRSF1 13 
protein on BCL2L1 and BIM pre-mRNAs was evaluated using primers encompassing the junction 14 
between exon 2 and intron 2. B. Representative images of PLA assays shown in Figure 3E 15 
analyzing the interaction between SRSF1 and mutant p53. Merged signals of DAPI and PLA are 16 
shown in the indicated cell lines. C. Representative images of MALAT1 staining obtained in RNA 17 
FISH analysis using fluorescence microscopy showing the presence of cells with “classical” 18 
speckled localization and cells showing a diffused staining in addition to the speckled localization 19 
of MALAT1. Scale bars, 10 µm. D-E. Western blot analysis of cell extracts derived by fractionation 20 
of lysates from MDA-MB-468 and SKBR3 cells, to obtain cytoplasmic, nuclear soluble and 21 
chromatin-associated nuclear fractions, performed using the indicated antibodies. 22 
 23 
Figure EV4. A. Western blot analysis of MDA-MB-468 cells interfered or not for hnRNP A1 24 
expression using 2 different concentrations of siRNAs. B. RT-qPCR analysis of two isoforms of 25 
Aldolase A mRNA (ALDOA) differing for the inclusion/exclusion of exon 2. Ratio of Exon 2 26 
38 
 
excluding isoform vs Exon 2 including isoform is presented. C-F. Representative western blot 1 
experiments of SKBR3 (C, E, G), MDA-MB-231 (D) and MDA-MB-468 (F, G) cells transfected 2 
with the indicated siRNAs to p53, ID4, SRSF1 or MALAT1. Numbers indicate the ratio of 3 
VEGF165b vs total VEGFA proteins. MALAT1 and ID4 depletion was assessed by RT-qPCR (H). 4 
Different siRNAs were used for each factor.  5 
 6 
Figure EV5. Kaplan-Meier analyses representing the correlation between the expression of ID4 7 
mRNA (panel A), 16-VEGFA signature (panel B), or their combination (panel C), and overall 8 
survival in 201 basal-like breast cancer patients from the Breast Cancer Compendium cohort. 9 
Tumours were divided into high- or low-ID4 expression categories based on the median of ID4 10 
expression in the series. 11 
 12 
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